Cargando…

Management of sexual dysfunction in breast cancer survivors: a systematic review

Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are under-diagnosed and under-treated in BCS. The objective of this review was to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Seav, Susan M., Dominick, Sally A., Stepanyuk, Boris, Gorman, Jessica R., Chingos, Diana T., Ehren, Jennifer L., Krychman, Michael L., Su, H. Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297963/
https://www.ncbi.nlm.nih.gov/pubmed/30766696
http://dx.doi.org/10.1186/s40695-015-0009-4
_version_ 1783381236368015360
author Seav, Susan M.
Dominick, Sally A.
Stepanyuk, Boris
Gorman, Jessica R.
Chingos, Diana T.
Ehren, Jennifer L.
Krychman, Michael L.
Su, H. Irene
author_facet Seav, Susan M.
Dominick, Sally A.
Stepanyuk, Boris
Gorman, Jessica R.
Chingos, Diana T.
Ehren, Jennifer L.
Krychman, Michael L.
Su, H. Irene
author_sort Seav, Susan M.
collection PubMed
description Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are under-diagnosed and under-treated in BCS. The objective of this review was to assess primary studies that intervene on sexual dysfunction in BCS. In February 2015, PubMed, SCOPUS, CINAHL, COCHRANE and Web of Science databases were systematically searched for randomized controlled clinical trials (RCTs) of vaginal (lubricants, moisturizers, estrogens, dehydroepiandrosterone [DHEA], testosterone, vibrators, dilators), systemic (androgens, anti-depressants, flibanserin, ospemifene), physical therapy (physical activity, pelvic floor training), counseling and educational interventions on sexual function in BCS. Observational studies of vaginal interventions were also included due to the paucity of RCTs. The search yielded 1414 studies, 34 of which met inclusion criteria. Both interventions and outcomes, measured by 31 different sexual function scales, were heterogeneous, and therefore data were not pooled. The review found that regular and prolonged use of vaginal moisturizers was effective in improving vaginal dryness, dyspareunia, and sexual satisfaction. Educational and counseling interventions targeting sexual dysfunction showed consistent improvement in various aspects of sexual health. No consistent improvements in sexual health were observed with physical activity, transdermal testosterone or hot flash interventions. There was a lack of BCS-specific data on vaginal lubricants, vibrators, dilators, pelvic floor therapy, flibanserin or ospemifene. Overall, the quality of evidence for these studies was moderate to very low. Because each of the interventions with BCS data had limited efficacy, clinical trials to test novel interventions are needed to provide evidence-based clinical recommendations and improve sexual function in BCS.
format Online
Article
Text
id pubmed-6297963
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62979632019-02-14 Management of sexual dysfunction in breast cancer survivors: a systematic review Seav, Susan M. Dominick, Sally A. Stepanyuk, Boris Gorman, Jessica R. Chingos, Diana T. Ehren, Jennifer L. Krychman, Michael L. Su, H. Irene Womens Midlife Health Review Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are under-diagnosed and under-treated in BCS. The objective of this review was to assess primary studies that intervene on sexual dysfunction in BCS. In February 2015, PubMed, SCOPUS, CINAHL, COCHRANE and Web of Science databases were systematically searched for randomized controlled clinical trials (RCTs) of vaginal (lubricants, moisturizers, estrogens, dehydroepiandrosterone [DHEA], testosterone, vibrators, dilators), systemic (androgens, anti-depressants, flibanserin, ospemifene), physical therapy (physical activity, pelvic floor training), counseling and educational interventions on sexual function in BCS. Observational studies of vaginal interventions were also included due to the paucity of RCTs. The search yielded 1414 studies, 34 of which met inclusion criteria. Both interventions and outcomes, measured by 31 different sexual function scales, were heterogeneous, and therefore data were not pooled. The review found that regular and prolonged use of vaginal moisturizers was effective in improving vaginal dryness, dyspareunia, and sexual satisfaction. Educational and counseling interventions targeting sexual dysfunction showed consistent improvement in various aspects of sexual health. No consistent improvements in sexual health were observed with physical activity, transdermal testosterone or hot flash interventions. There was a lack of BCS-specific data on vaginal lubricants, vibrators, dilators, pelvic floor therapy, flibanserin or ospemifene. Overall, the quality of evidence for these studies was moderate to very low. Because each of the interventions with BCS data had limited efficacy, clinical trials to test novel interventions are needed to provide evidence-based clinical recommendations and improve sexual function in BCS. BioMed Central 2015-11-02 /pmc/articles/PMC6297963/ /pubmed/30766696 http://dx.doi.org/10.1186/s40695-015-0009-4 Text en © Seav et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Seav, Susan M.
Dominick, Sally A.
Stepanyuk, Boris
Gorman, Jessica R.
Chingos, Diana T.
Ehren, Jennifer L.
Krychman, Michael L.
Su, H. Irene
Management of sexual dysfunction in breast cancer survivors: a systematic review
title Management of sexual dysfunction in breast cancer survivors: a systematic review
title_full Management of sexual dysfunction in breast cancer survivors: a systematic review
title_fullStr Management of sexual dysfunction in breast cancer survivors: a systematic review
title_full_unstemmed Management of sexual dysfunction in breast cancer survivors: a systematic review
title_short Management of sexual dysfunction in breast cancer survivors: a systematic review
title_sort management of sexual dysfunction in breast cancer survivors: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297963/
https://www.ncbi.nlm.nih.gov/pubmed/30766696
http://dx.doi.org/10.1186/s40695-015-0009-4
work_keys_str_mv AT seavsusanm managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT dominicksallya managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT stepanyukboris managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT gormanjessicar managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT chingosdianat managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT ehrenjenniferl managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT krychmanmichaell managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview
AT suhirene managementofsexualdysfunctioninbreastcancersurvivorsasystematicreview